

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/021150-2023>

Planning

Accelerated Combined Sample Extraction and Whole Genome Sequencing Service

Genomics England

F01: Prior information notice

Prior information only

Notice identifier: 2023/S 000-021150

Procurement identifier (OCID): ocds-h6vhtk-03e45d

Published 21 July 2023, 2:55pm

Section I: Contracting authority

I.1) Name and addresses

Genomics England

One Canada Square

London

E14 5AB

Contact

Zoë Hallam

Email

supplier.engagement@genomicsengland.co.uk

Telephone

+44 2078825030

Country

United Kingdom

Region code

UKI - London

Internet address(es)

Main address

www.genomicsengland.co.uk

I.3) Communication

Additional information can be obtained from the above-mentioned address

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Accelerated Combined Sample Extraction and Whole Genome Sequencing Service

Reference number

GEL-HE-596-23

II.1.2) Main CPV code

- 71900000 - Laboratory services

II.1.3) Type of contract

Services

II.1.4) Short description

Accelerated and combined provision of sample extraction and whole genome sequencing for up to 80,000 newborn genomes

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.2) Additional CPV code(s)

- 71900000 - Laboratory services
- 73111000 - Research laboratory services

II.2.3) Place of performance

NUTS codes

- UKI - London

II.2.4) Description of the procurement

Genomics England is aiming to return any 'condition suspected' findings regarding an agreed list of 200+ severe conditions for which there is an intervention available early in

childhood to families in a timeframe which enables clinicians to order confirmatory tests and start therapeutic treatment. The optimal timeframe has been assessed as 14 working days, with 7 working days of this allocated to extraction and sequencing.

‘No condition suspected’ findings will be returned directly to participants and will not be subject to target turnaround times. However, as this is not known until sequencing is complete, the net impact is that all sequences should be delivered in the timelines described.

The study aims to develop ‘modular’ evidence for policy makers on sequencing as in other areas. For example, separating the evidence on the performance of specific sequencing platforms to detect a particular range of genomic variation from the evidence on the impact of using screening led by the detection of particular classes of genomic variation. This mirrors the ‘technology agnostic’ approach taken by NHS England in the NHS Genomic Test Directory.

To this end, Genomics England are considering a multi-supplier supply chain approach across technologies during the course of the study that enable the development of this evidence. With this approach the sequencing volumes can be delivered by multiple suppliers using a variety of technologies.

II.2.14) Additional information

Suppliers interested in engaging with Genomics England on this requirement are invited to register at www.genomicsengland.bravosolution.co.uk and apply to project_856.

II.3) Estimated date of publication of contract notice

16 October 2023

Section IV. Procedure

IV.1) Description

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No